Cancer Development and Progression in Patients with Heart Failure
Open Access
- 28 September 2024
- journal article
- review article
- Published by Springer Nature in Current Heart Failure Reports
- Vol. 21 (6) , 515-529
Abstract
Purpose of Review: The co-occurrence of heart failure (HF) and cancer represents a complex and multifaceted medical challenge. Patients with prevalent cardiovascular disease (CVD), particularly HF, exhibit an increased risk of cancer development, raising questions about the intricate interplay between these two prevalent conditions. This review aims to explore the evolving landscape of cancer development in patients with HF, shedding light on potential mechanisms, risk factors, and clinical implications. Recent Findings: Epidemiological data suggests higher cancer incidences and higher cancer mortality in HF patients, which are potentially more common in patients with HF with preserved ejection fraction due to related comorbidities. Moreover, recent preclinical data identified novel pathways and mediators including the protein SerpinA3 as potential drivers of cancer progression in HF patients, suggesting HF as an individual risk factor for cancer development. Summary: The review emphasizes preliminary evidence supporting cancer development in patients with HF, which offers several important clinical interventions such as cancer screening in HF patients, prevention addressing both HF and cancer, and molecular targets to treat cancer. However, there is need for more detailed understanding of molecular and cellular cross-talk between cancer and HF which can be derived from prospective assessments of cancer-related outcomes in CV trials and preclinical research of molecular mechanisms.Keywords
Funding Information
- Universitätsklinikum Köln
This publication has 84 references indexed in Scilit:
- Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trialsThe Lancet Oncology, 2011
- The renin–angiotensin system and cancer: old dog, new tricksNature Reviews Cancer, 2010
- Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trialsThe Lancet Oncology, 2010
- Hallmarks of cancer: Interactions with the tumor stromaExperimental Cell Research, 2010
- AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonistProceedings of the National Academy of Sciences, 2009
- Understanding the Warburg Effect: The Metabolic Requirements of Cell ProliferationScience, 2009
- Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinomaNature Medicine, 2006
- Captopril, an Angiotensin-Converting Enzyme Inhibitor, Promotes Growth of Immunogenic Tumors in MiceClinical Cancer Research, 2006
- Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failureJournal of Clinical Investigation, 2005
- Functional Expression of the Angiotensin II Type1 Receptor in Human Ovarian Carcinoma Cells and Its Blockade Therapy Resulting in Suppression of Tumor Invasion, Angiogenesis, and Peritoneal DisseminationClinical Cancer Research, 2005